Cardiff Oncology, Inc.(CRDF)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Cardiff Oncology, Inc. (CRDF) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRDF at 9.8/100 on a 32-signal composite quality model, placing it at rank #2,912 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Cardiff Oncology, Inc. reports quarterly revenue of $104.0K, net income of $-9.2M. Top institutional holders of CRDF by reported 13-F value include Laurion Capital Management, VANGUARD CAPITAL MANAGEMENT, PFIZER, based on the most recent SEC filings. CRDF trades on the Nasdaq exchange and files with the SEC under CIK 1213037. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRDF daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cardiff Oncology, Inc. directly from SEC EDGAR.
AI Quality Score
9.8/100
AI Rank
#2,912
Revenue
$104.0K
Net Income
$-9.2M
CRDF key financials by period
Cardiff Oncology, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$593.0K
$-45.9M
—
FY 2024
10-K
$683.0K
$-45.4M
—
FY 2023
10-K
$488.0K
$-41.4M
—
FY 2022
10-K
$386.0K
$-38.7M
—
FY 2021
10-K
$359.0K
$-28.3M
—
FY 2020
10-K
$366.0K
$-19.3M
—
Institutions holding CRDF
Institutional investors reporting a position in Cardiff Oncology, Inc. on SEC Form 13F.
